MEDIHONEY Used to Prevent Amputation of Patient's Leg

Clinicians at major NY hospital tout MEDIHONEY(TM) at press conference

PRINCETON, N.J., Jan. 13 /PRNewswire-FirstCall/ -- Derma Sciences, Inc. (OTCBulletinBoard: DSCI) , a provider of advanced wound care products, announced today that MEDIHONEY was the focus of a major press conference last week at North Shore Long Island Jewish Hospital in Manhasset, NY. At the press conference, clinicians detailed the case of a patient who appeared to be heading towards a lower extremity amputation (LEA) due to a non-healing wound associated with an extremely rare fungal infection.

Video clips of the press conference were subsequently aired on several new broadcasts throughout the NY region. To view these clips, please go to the following links:

http://www.newsday.com/news/health/ny-lihone0109,0,7667575.story

http://abclocal.go.com/wabc/story?section=news/health&id=6593764

According to Mary Brennan, RN, CWOCN, Clinical Nurse Specialist for Wounds at North Shore, "MEDIHONEY helped to turn this wound around for him and allowed us back on track for healing. We had used other therapies, but this was the product that made the difference in a very short time."

There are over 50,000 LEAs each year in the United States alone. The 3-year mortality rate post-LEA is estimated to be around 50%.

About Derma Sciences

Derma Sciences is a global manufacturer and marketer of advanced wound-care products. Its key product, MEDIHONEY(R), is sold throughout the world by Derma Sciences and Comvita New Zealand -- the licensor of the patented honey- based technology -- and is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown to be effective in a variety of wounds and burns, and was recently the focus of a large-scale randomized controlled trial on leg ulcers. Derma has two products in development: the BIOGUARD(TM) line of barrier gauze dressings, and DSC127, the company's novel angiotensin analog for accelerated wound healing and scar reduction. The barrier technology was licensed from Quick-Med in Q1 of 2007 and is pending its initial FDA marketing clearance. DSC127 was licensed from the University of Southern California in Q4 of 2007. For more information about Derma Sciences, Inc., visit its home page on the Internet at http://www.dermasciences.com.

    Contact: Derma Sciences, Inc.             Allen & Caron Inc
             Edward J. Quilty                 Rudy Barrio (US Investors)
             Chairman and CEO                 r.barrio@allencaron.com
             equilty@dermasciences.com
             (609) 514-4744                   Brian Kennedy (media)
                                              brian@allencaron.com
                                              (212) 691-8087